Oppenheimer & Co. Inc. decreased its position in Chemed Corp. (NYSE:CHE) by 7.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,518 shares of the company’s stock after selling 2,845 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.22% of Chemed Corp. worth $7,177,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Kalos Management Inc. grew its position in shares of Chemed Corp. by 0.7% during the second quarter. Kalos Management Inc. now owns 6,521 shares of the company’s stock worth $1,333,000 after purchasing an additional 45 shares in the last quarter. Capstone Asset Management Co. grew its position in shares of Chemed Corp. by 2.7% during the second quarter. Capstone Asset Management Co. now owns 1,857 shares of the company’s stock worth $380,000 after purchasing an additional 49 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Chemed Corp. by 0.4% during the second quarter. Nisa Investment Advisors LLC now owns 11,600 shares of the company’s stock worth $2,373,000 after purchasing an additional 50 shares in the last quarter. Amalgamated Bank grew its position in shares of Chemed Corp. by 2.9% during the second quarter. Amalgamated Bank now owns 2,203 shares of the company’s stock worth $451,000 after purchasing an additional 62 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in shares of Chemed Corp. by 0.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 8,681 shares of the company’s stock worth $1,776,000 after purchasing an additional 64 shares in the last quarter. 96.50% of the stock is currently owned by institutional investors.

CHE has been the subject of several research analyst reports. TheStreet upgraded Chemed Corp. from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price target for the company in a report on Friday, July 28th. Royal Bank Of Canada restated a “hold” rating and set a $209.00 price target on shares of Chemed Corp. in a report on Friday, September 1st. Finally, BidaskClub cut Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $236.00.

In other news, insider Spencer S. Lee sold 1,000 shares of Chemed Corp. stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total value of $197,460.00. Following the completion of the transaction, the insider now owns 37,809 shares in the company, valued at approximately $7,465,765.14. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Michael D. Witzeman sold 1,579 shares of Chemed Corp. stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $235.00, for a total value of $371,065.00. Following the completion of the transaction, the vice president now owns 4,334 shares of the company’s stock, valued at approximately $1,018,490. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,229 shares of company stock valued at $7,794,718. Company insiders own 4.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/24/oppenheimer-co-inc-sells-2845-shares-of-chemed-corp-che.html.

Chemed Corp. (CHE) opened at $238.16 on Friday. The company has a market capitalization of $3,802.46, a P/E ratio of 29.33, a PEG ratio of 5.04 and a beta of 1.14. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15. Chemed Corp. has a 1-year low of $145.35 and a 1-year high of $241.57.

Chemed Corp. (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.15. The firm had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.73 EPS. research analysts forecast that Chemed Corp. will post 4.73 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Stockholders of record on Monday, November 13th will be issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Friday, November 10th. Chemed Corp.’s dividend payout ratio (DPR) is 24.89%.

Chemed Corp. Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Institutional Ownership by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Stock Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related stocks with our FREE daily email newsletter.